ASCO 2023 | The CONnected CUstomized Treatment Platform in patients with metastatic BC receiving palbociclib

Ilana Graetz, PhD, Emory University, Atlanta, GA, discusses a study aimed to pilot test a mobile health intervention, the CONnected CUstomized Treatment Platform, in women with hormone receptor-positive, metastatic breast cancer. The intervention included a smartbox for real-time adherence monitoring, text message reminders for missed or extra doses, and referrals to the oncology provider or a financial navigation program as needed. Out of 29 participants, 72.4% used the smartbox, and the adherence rate for palbociclib was 95.8% ± 7.6%. Only a few participants had adherence barriers at baseline. There were no significant changes in self-reported adherence, symptom burden, or quality of life over three months. The usability score of the CONnected CUstomized Treatment Platform was 61.9 ± 14.2. The study concluded that the intervention was feasible and resulted in high adherence, but further improvements in usability should be explored. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.